Investing.com -- The life sciences and diagnostic tools sector is poised for growth in 2026, with several companies well-positioned to capitalize on improving market conditions. According to Bank of America’s latest analysis, these companies offer compelling investment opportunities based on innovation, market positioning, and growth potential.
Get premium news and insight, AI stock picks, and deep research tools by upgrading to InvestingPro - get 55% off today
Thermo Fisher Scientific emerges as BofA’s top pick within the Life Sciences Tools industry. The bank has raised its price objective to $700 while reiterating a Buy rating. TMO’s management has guided to fiscal year 2026 topline growth of 3-4% and over 50 basis points of operating margin expansion, excluding benefits from the Clario acquisition, which is expected to be 45 cents accretive in year one. The company should benefit from sector tailwinds including reshoring and easing uncertainty in academic, government, and pharmaceutical end-markets. TMO’s innovation and commitment to being the "trusted partner" are expected to drive continued momentum.
In recent developments, Thermo Fisher Scientific has received several positive analyst ratings, including an upgrade to Overweight from KeyBanc and new Overweight or Buy ratings from Morgan Stanley and Goldman Sachs. The company also announced an expansion of its bioprocessing capabilities across Asia to support the region’s growing biopharmaceutical industry.
IQVIA Holdings enters 2026 with a more constructive and de-risked setup. Management commentary points to at least similar top-line growth next year (approximately 5% reported), reflecting growing confidence in the demand environment. Decision cycles are shortening, and RFP flow has become more consistent, contributing to a more predictable backdrop despite uneven sector growth. The Technology & Analytics Solutions segment should remain steady, supported by continued customer engagement and adoption of analytics and AI tools. BofA has raised its price objective to $260 and maintains a Buy rating, citing IQV’s strong underlying long-term fundamentals and competitive position in the Phase I-IV space.
IQVIA Holdings has entered into a strategic collaboration with Amazon Web Services (AWS), designating it as a preferred cloud provider to enhance its AI platform for clinical trials and healthcare analytics. Additionally, Stifel raised its price target on the company, while Morgan Stanley initiated coverage with an Overweight rating.
Guardant Health is positioned as a logical beneficiary of growth in molecular diagnostic testing, particularly liquid biopsy. The company enters 2026 with strong momentum as legacy offerings like G360 Liquid remain early in their adoption curve. GH stands out with a comprehensive portfolio across the cancer care continuum. Key catalysts include Reveal’s expansion into breast cancer treatments, anticipated FDA approval for G360 Liquid, and accelerating Shield adoption through partnerships. BofA has raised its price objective to $120 and reiterates a Buy rating, seeing potential upside not reflected in current estimates.
Guardant Health recently expanded its Guardant Reveal blood test to include therapy response monitoring for patients with advanced solid tumors. The company also saw positive analyst actions, with Jefferies raising its price target and BTIG naming it a top pick for 2026.
Elanco Animal Health is BofA’s top pick within Animal Health coverage, supported by a reinvigorated product portfolio and key launches. Despite sector headwinds from muted veterinary visits and consumer pressures, ELAN’s strong pipeline (including Befrena) and successful launches (Credelio Quattro, Zenrelia) provide a clear path to sustained growth. The company’s insulation from clinic traffic further differentiates it from peers with higher exposure, positioning it to better navigate a challenging macro environment. BofA maintains its price objective at $25.
Elanco Animal Health received conditional approval from the U.S. Food and Drug Administration for its Credelio Quattro-CA1 product as a treatment for New World screwworm larvae infestations in dogs. The company also continued to receive positive analyst sentiment, with Leerink Partners raising its price target and both Stifel and KeyBanc maintaining their positive ratings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.























